Oxford Immunotec
PerkinElmer's Oxford Immunotec Gains FDA Go-Ahead for TB Test Automation
The PerkinElmer subsidiary said its T-Cell Select reagent kit reduces hands-on lab work and cost and simplifies blood sample storage.
Qiagen Next-Gen QuantiFeron Tuberculosis Test Gains Chinese Regulatory Approval
The new approval for QuantiFeron-TB Gold Plus adds to prior regulatory approvals in the US and other countries around the world, including CE-IVD marking.
The firm has obtained CE marking for its automated, sample-to-answer Vidas TB-IGRA test for latent TB and is preparing a submission for FDA clearance.
Oxford Immunotec Nabs CE Mark for COVID-19 T-Cell Response Test
The firm said its T-cell test complements serology testing and provides a more comprehensive view of the adaptive immune response to SARS-CoV-2 infection.
Oxford Immunotec, Valneva Collaborate on COVID-19 Vaccine Study
Oxford Immunotec's T-Spot Discovery SARC-CoV-2 test will be used to assess whether Valneva's vaccine candidate induces a T-cell response.
Jan 7, 2021
PerkinElmer to Buy Oxford Immunotec for $591M
May 5, 2020